- Market Capitalization, $K 348,261
- Shares Outstanding, K 38,397
- Annual Sales, $ 8,190 K
- Annual Income, $ -49,040 K
- 60-Month Beta 1.37
- Price/Sales 42.50
- Price/Cash Flow N/A
- Price/Book 1.37
|Period||Period Low||Period High||Performance|
| || |
+0.41 (+4.39%)since 07/02/21
| || |
-4.22 (-30.21%)since 05/03/21
| || |
-17.50 (-64.22%)since 08/03/20
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/PRNewswire/ -- New COVID-19 cases continue to surge throughout , causing municipal governments to spring into action to combat the rising number of the highly infectious Delta variant cases. On Monday,...
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHEK, WISH, MRIN, ATOS, and ALT.
Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT.
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLOV, EDU, ALT, BB, and MVIS.
via NewMediaWire -- Pan-European independent power producer ("IPP"), Alternus Energy Group Plc (NOTC: ALT) (the "Company" or "Alternus"), is excited to announce the recent acquisition of 60% of the share...
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, BB, IDEX, SEEL, and ALT.
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare...